Your browser doesn't support javascript.
loading
Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines.
Ou, Ben S; Baillet, Julie; Picece, Vittoria C T M; Gale, Emily C; Powell, Abigail E; Saouaf, Olivia M; Yan, Jerry; Nejatfard, Anahita; Lopez Hernandez, Hector; Appel, Eric A.
Afiliación
  • Ou BS; Department of Bioengineering, Stanford University, Stanford, California 94305, United States.
  • Baillet J; Department of Materials Science & Engineering, Stanford University, Stanford, California 94305, United States.
  • Picece VCTM; Department of Materials Science & Engineering, Stanford University, Stanford, California 94305, United States.
  • Gale EC; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich 8093, Switzerland.
  • Powell AE; Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, United States.
  • Saouaf OM; Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, United States.
  • Yan J; Stanford ChEM-H, Stanford University, Stanford, California 94305, United States.
  • Nejatfard A; Department of Materials Science & Engineering, Stanford University, Stanford, California 94305, United States.
  • Lopez Hernandez H; Department of Bioengineering, Stanford University, Stanford, California 94305, United States.
  • Appel EA; Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305, United States.
ACS Nano ; 18(4): 3214-3233, 2024 Jan 30.
Article en En | MEDLINE | ID: mdl-38215338
ABSTRACT
Development of effective vaccines for infectious diseases has been one of the most successful global health interventions in history. Though, while ideal subunit vaccines strongly rely on antigen and adjuvant(s) selection, the mode and time scale of exposure to the immune system has often been overlooked. Unfortunately, poor control over the delivery of many adjuvants, which play a key role in enhancing the quality and potency of immune responses, can limit their efficacy and cause off-target toxicities. There is a critical need for improved adjuvant delivery technologies to enhance their efficacy and boost vaccine performance. Nanoparticles have been shown to be ideal carriers for improving antigen delivery due to their shape and size, which mimic viral structures but have been generally less explored for adjuvant delivery. Here, we describe the design of self-assembled poly(ethylene glycol)-b-poly(lactic acid) nanoparticles decorated with CpG, a potent TLR9 agonist, to increase adjuvanticity in COVID-19 vaccines. By controlling the surface density of CpG, we show that intermediate valency is a key factor for TLR9 activation of immune cells. When delivered with the SARS-CoV-2 spike protein, CpG nanoparticle (CpG-NP) adjuvant greatly improves the magnitude and duration of antibody responses when compared to soluble CpG, and results in overall greater breadth of immunity against variants of concern. Moreover, encapsulation of CpG-NP into injectable polymeric-nanoparticle (PNP) hydrogels enhances the spatiotemporal control over codelivery of CpG-NP adjuvant and spike protein antigen such that a single immunization of hydrogel-based vaccines generates humoral responses comparable to those of a typical prime-boost regimen of soluble vaccines. These delivery technologies can potentially reduce the costs and burden of clinical vaccination, both of which are key elements in fighting a pandemic.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD Problema de salud: 1_doencas_nao_transmissiveis / 2_cobertura_universal / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_pneumonia Asunto principal: Vacunas / Nanopartículas / Glicoproteína de la Espiga del Coronavirus / COVID-19 Límite: Humans Idioma: En Revista: ACS Nano Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD Problema de salud: 1_doencas_nao_transmissiveis / 2_cobertura_universal / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_pneumonia Asunto principal: Vacunas / Nanopartículas / Glicoproteína de la Espiga del Coronavirus / COVID-19 Límite: Humans Idioma: En Revista: ACS Nano Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...